Printer friendly version
Cancer: Another step towards medication - Austrian Scientists identify a potential tumor suppressor
18 March 2009
University of Innsbruck
The gene Myc is an important factor for the growth of organisms by cell division. It causes the production of a protein which, as a transcription factor, controls the expression of up to 15 % of all human genes. When this gene mutates to an oncogene, the cell proliferates excessively and apoptosis is inhibited. Thereby the gene plays a decisive role in the development of many tumors. The problem is that pharmacological substances do not target Myc as it does not have enzymatic activity of its own. Thus, scientists worldwide are trying to find alternative ways to inhibit this oncogene. A team of scientists led by Klaus Bister and Markus Hartl of the Institute of Biochemistry and the Centre for Molecular Biosciences of the University of Innsbruck may have made an important step towards achieving this goal.
Suppressing pathological cell growth
For the first time, the scientists have shown that Myc suppresses the expression of the gene BASP1. This evidence prompted them to test the effect of BASP1 on the oncogene. In cell experiments they proved that BASP1 specifically inhibits the uncontrolled proliferation of Myc. „Until now the precise biochemical function of BASP1 is unknown“, Prof. Bister explains. „However, in our experiments we have found clear evidence that Myc-induced cell transformation can be specifically inhibited by BASP1, and consequently, the gene functions as a tumor suppressor.“ This finding may facilitate the development of new drugs which keep the development of tumors under control.
The team of Bister published the findings in the online edition of the American journal Proceedings of the National Academy of Sciences (PNAS). The scientists are supported by the Austrian Science Fund.
Onkogen Myc induces cell transformation (left), tumor suppressor BASP1 inhibits the Myc induced cell transformation (right).
Markus Hartl (left) and Professor Klaus Bister (right) from the Institute of Biochemistry at the University of Innsbruck, Austria